HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Langerhans' cell histiocytosis — Clinical Guidelines

Overview

Langerhans cell histiocytosis (LCH) is a rare disorder characterized by the abnormal proliferation of Langerhans-like cells, affecting multiple organs including bone, skin, and lungs, with varying clinical severity 1 2 6 7.

Diagnosis

Clinical Presentation: Varies widely, from single bone lesions to multisystem involvement 2 6.

Imaging: Useful for detecting organ involvement, particularly MRI for spinal lesions 12.

Biopsy: Essential for definitive diagnosis, often showing CD1a+ cells 4 12.

Histological Features: Characterized by Langerhans cell infiltration and associated granulomatous inflammation 4 9.

Special Cases: Congenital LCH can present as severe multiorgan disease, including hydrops fetalis 7.

Management

First-Line Treatment: Prednisolone is commonly used, often in combination with cytarabine and vincristine for multisystem disease 3 5.

Intensified Therapy: Induction regimen of cytarabine, vincristine, and prednisolone for 6 weeks followed by maintenance therapy improves outcomes in multisystem LCH 3.

Adjunctive Treatments: Continuous arteriovenous hemofiltration for managing tumor lysis syndrome 10.

Monitoring: Close monitoring for complications such as fatty liver disease and multi-organ failure, especially in adults 5.

Special Populations

Pediatrics: Appropriate management can prevent complications and improve quality of life; mortality rates are low with current protocols 2 3.

Adults: Rapid progression and multi-organ failure are more common; intensified therapy may be necessary 5.

Comorbidities: Cases with immunodeficiency or HIV-like symptoms require careful monitoring and tailored treatment 14.

Key Recommendations

Initiate Prednisolone-based therapy for localized disease and intensified regimens (cytarabine, vincristine, prednisolone) for multisystem involvement (Evidence: Strong 3).

Utilize MRI for guiding biopsies and assessing disease activity in spinal LCH (Evidence: Moderate 12).

Monitor for and manage complications such as tumor lysis syndrome with advanced renal support techniques (Evidence: Moderate 10).

Tailor treatment approaches based on patient age and extent of organ involvement (Evidence: Expert opinion 2 5).

References

1 Kiyak M, Tanoglu A, Yilmaz D. Langerhans Cell Histiocytosis with an Undetected Ileal Polyp. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 2022. link 2 Raciborska A, Bilska K, Węcławek-Tompol J, Gryniewicz-Kwiatkowska O, Hnatko-Kołacz M, Stefanowicz J et al.. Clinical characteristics and outcome of pediatric patients diagnosed with Langerhans cell histiocytosis in pediatric hematology and oncology centers in Poland. BMC cancer 2020. link 3 Morimoto A, Shioda Y, Imamura T, Kudo K, Kawaguchi H, Sakashita K et al.. Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study. International journal of hematology 2016. link 4 Harikumar PE, Selway JL, Chu A, Langlands K. Collagen remodeling and peripheral immune cell recruitment characterizes the cutaneous Langerhans cell histiocytosis microenvironment. International journal of dermatology 2015. link 5 Yuasa M, Fujiwara S, Oh I, Yamaguchi T, Fukushima N, Morimoto A et al.. Rapidly progressing fatal adult multi-organ Langerhans cell histiocytosis complicated with fatty liver disease. Journal of clinical and experimental hematopathology : JCEH 2012. link 6 Schmidt S, Eich G, Geoffray A, Hanquinet S, Waibel P, Wolf R et al.. Extraosseous langerhans cell histiocytosis in children. Radiographics : a review publication of the Radiological Society of North America, Inc 2008. link 7 Lee CH, Lau TK, To KF, Lam HS, Chan AW, Ng PC. Congenital systemic Langerhans cell histiocytosis presenting as hydrops fetalis. Acta paediatrica (Oslo, Norway : 1992) 2005. link 8 Davis SE, Rice DH. Langerhans' cell histiocytosis: current trends and the role of the head and neck surgeon. Ear, nose, & throat journal 2004. link 9 Papla B, Malinowski E, Nizankowska-Mogilnicka E, Bochenek G. Pulmonary langerhans cell granulomatosis. A study of 11 cases. Polish journal of pathology : official journal of the Polish Society of Pathologists 2003. link 10 Jaing TH, Hsueh C, Tain YL, Hung IJ, Hsia SH, Kao CC. Tumor lysis syndrome in an infant with Langerhans cell histiocytosis successfully treated using continuous arteriovenous hemofiltration. Journal of pediatric hematology/oncology 2001. link 11 Malkoç N, Topaloğlu R, Ozön A, Turanli G, Bilginturan N. Langerhans' cell histiocytosis: report of an atypical case. Journal of pediatric endocrinology & metabolism : JPEM 2000. link 12 Kaplan GR, Saifuddin A, Pringle JA, Noordeen MH, Mehta MH. Langerhans' cell histiocytosis of the spine: use of MRI in guiding biopsy. Skeletal radiology 1998. link 13 Soler P, Kambouchner M, Valeyre D, Hance AJ. Pulmonary Langerhans' cell granulomatosis (histiocytosis X). Annual review of medicine 1992. link 14 Manna A, Porcellini A, Marelli A, Bianchini E, Pialoux G. A case of Langerhans histiocytosis with HIV-like immunodeficiency. Haematologica 1992. link 15 Lieberman PH, Jones CR, Filippa DA. Langerhans cell (eosinophilic) granulomatosis. The Journal of investigative dermatology 1980. link

Langerhans' cell histiocytosis